Back |
home / stock / clsn / clsn message board
Subject | By | Source | When |
---|---|---|---|
wait till Monday big news coming, buy now | trity | investorshub | 01/30/2021 7:13:22 PM |
* * $CLSN Video Chart 01-26-2021 * * | ClayTrader | investorshub | 01/26/2021 9:30:22 PM |
im better than you bought at 0.85 sold | sollyman | investorshub | 01/24/2021 5:25:56 PM |
bought at .88 Sold at 2.75 | rickhenderson | investorshub | 01/24/2021 4:24:22 PM |
Really? This stock was once 500$ a share? | CannabidiolHead | investorshub | 01/22/2021 11:42:09 PM |
Tutes are planning to make money so relax! | tommer | investorshub | 01/22/2021 9:38:24 PM |
I was disappointed to see this offering of | blh28 | investorshub | 01/22/2021 8:18:09 PM |
https://ih.advfn.com/stock-market/NASDAQ/celsion-$CLSN/stock-news/84150415/celsio | tommer | investorshub | 01/22/2021 2:13:25 PM |
time to push this stock higher | trity | investorshub | 01/22/2021 12:05:32 PM |
A good buying day. Big news on a | trity | investorshub | 01/22/2021 11:30:10 AM |
* * $CLSN Video Chart 01-21-2021 * * | ClayTrader | investorshub | 01/21/2021 9:00:47 PM |
sold half at 2.50 - playing with house | janeyH | investorshub | 01/21/2021 4:02:38 PM |
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...